|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2006-6-7
|
|
pubmed:abstractText |
Rifampicin greatly reduces the plasma concentrations of many drugs. Our aim was to characterise the inducibility of cytochrome P450 (CYP) 1A2 by rifampicin, using tizanidine and caffeine as probe drugs for presystemic and systemic CYP1A2-mediated metabolism.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0031-6970
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
62
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
451-61
|
|
pubmed:meshHeading |
pubmed-meshheading:16758262-Adult,
pubmed-meshheading:16758262-Anti-Bacterial Agents,
pubmed-meshheading:16758262-Blood Pressure,
pubmed-meshheading:16758262-Caffeine,
pubmed-meshheading:16758262-Clonidine,
pubmed-meshheading:16758262-Cross-Over Studies,
pubmed-meshheading:16758262-Cytochrome P-450 CYP1A2,
pubmed-meshheading:16758262-Drug Interactions,
pubmed-meshheading:16758262-Enzyme Induction,
pubmed-meshheading:16758262-Female,
pubmed-meshheading:16758262-Heart Rate,
pubmed-meshheading:16758262-Humans,
pubmed-meshheading:16758262-Male,
pubmed-meshheading:16758262-Rifampin
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.
|
|
pubmed:affiliation |
Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland. janne.backman@hus.fi
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
